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Who and what makes a cancer phase 1 trial 
and why are they so important?
First in Human
Report
Please cite this project using the following DOI: 
10.17605/OSF.IO/KWHQF
Phase 1 clinical trials assess new cancer treatments in people for the 
first time. Bringing new cancer therapies into routine cancer care is a 
long and complex process. It is a critical step in the pathway. The aim 
of this project is to define and communicate the world of a cancer 
Phase 1 trialist, and the value they bring. 
Through a deeper understanding and insight of those involved, we 
hope this will benefit those interested in careers in cancer clinical 
trials, stakeholders and partners seeking to innovate across the 
cancer control continuum.
Phase one trials are small in scale, with a limited number of patients. 
These trials usually recruit patients who have exhausted other 
treatment options.
The aim of phase 1 trials is to explore doses and side effects. Trials 
don’t offer benefits to participants - However, other people may 
benefit from the new treatment in the future.
For any information, please contact:
Gaston Welisch - gastonwelisch@gmail.com
Nicol Keith - nicol.keith@glasgow.ac.uk
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A community of senior and early career oncologists were asked 
to participate in group consultations and individual interviews 
to reflect on the importance of Phase 1 trials, who makes 
them possible, the value of networks, and the challenges and 
opportunities presented by the COVID-19 pandemic. Over the 
following components, you will see quotes and summaries of 
what emerged from these sessions.
The participants’ discussions were written down during the 
sessions using a digital collaboration platform (Miro), and were 
then also transcribed using the recordings. For the analysis, we 
focused on important recurring themes, classifying them within 
the structure used during the consultations. 
 
Cancer experts were pooled from the UK Experimental Cancer 
Medicine Centres (ECMCs) network, Clinical Trials Units and 
University Cancer Institutes as well as internationally from 
Malawi. Participants ranged from early career clinical fellows 
to senior clinical academics and research scientists. Expertise 
ranged from phase one specialists, heads of clinical trials units, 




Phase 1 trials safeguard cancer patients and  
enable future therapies with empathy. 
Participants were asked about the 
particularities of phase 1 trials in cancer 




Phase 1 trials safeguard the patients by gatekeeping the drugs 
and treatments that have unacceptable toxicity or limited 
efficacy.
“(Phase 1 trials are) the infrastructure within which to learn. It’s 
not just about recruiting the patients and collecting the data. It is 
the understanding of drug action that can allow you then to make 
sensible decisions about taking the drug forward into later phase 
trials.”
“(...) saying, look, I think we should drop this drug now because 
either from an unacceptable toxicity which cannot be overcome 
by any other strategy, or because of lack of efficacy and being 
brave enough to say, just pull the plug on this drug at this 
point now, or I don’t think this one’s going to go forward in (a) 
competitive environment.”
Phase 1 trials enable promising future treatments to go forward 
into later phase trials by being the first step of testing in human 
patients.
«If there are good new drugs coming through, and we have seen 
a huge number of really powerful and cheap practice changing 
drugs come through in the last 10 to 20 years, what you want 
is as fast as possible, that we get access for patients within the 
health service. And there are lots of factors that play into when 
those regulatory processes go through. And having active clinical 
trials and clinical research is a really important starting point for 
a country to keep its health service moving forward.»
«Almost all of the patients we talk to get the fact that if they 




Patients in phase one trials are usually terminal and have exhausted standard treatment options.
These trials are very intensive and challenging for patients, especially since they may already have 
had a long cancer journey at this point. Being part of a trial means more hospital visits, procedures 
and commitments. Trialists need to be open to patients to gain informed consent, explain that they 
are not offering benefits and make sure the patients understand the implications correctly and that 
the trial is right for them.
“I used to invite the administrative staff into the clinic, basically, so they could see (that) this isn’t 
just a paper or electronic exercise. So I think that you (need to) appreciate seeing the patient facing 
side of things.”
“(There is) this balance between not destroying hope, while not encouraging unrealistic 
expectations, being able to transition them so that you’re providing both the supportive care that 
they are going to need, if and when they leave the clinical trial.”
“I think it’s a special and different relationship with the patients. And the level of gratitude of 
patients is really humbling.”
We ask the patients with terminal 
cancer if they’re prepared to take 
an experimental drug, where we 
don’t know the dose and we don’t 
necessarily know the side effects. ”
“
URGENCY
There is a limited window of opportunity for patients to take part 
in Phase 1 trials, so it is important for patients to be aware of 
their options at the right moment.
“And one of the challenges we have when patients are running 
out of treatment options is whether their attending clinician 
says to them, we’ve run out of treatment options. And things are 
likely to get more difficult. Do you want to think about a trial? Or 
whether the treating physician simply says, well, we’ll give you a 
break off treatment at the moment and see you in three months 
time? And if you do the latter, then the window for an early 





The smaller scale of Phase 1 trials creates a unique dynamic, not found in later phase trials. 
Oncologists get to know the patients better, which is important on a human level, but also gives the 
opportunity to develop pattern recognition to spot subtle unexpected side effects or toxicity. Trialist 
also get to have an important impact on the development of new drugs and treatments at an early 
stage.
“We tend to see the early phase trial patients more frequently. So we tend to be a smaller team 
looking after the early phase trial patients so others see if they’re agreeable, I find myself getting to 
know these patients better.”
“So there is a more intimate relationship with the development of a drug and the ability to shape 
how that drug is developed. The proximity to the action, and the sense that you’re dealing with 
something that is genuinely novel, you’re giving a chemical to people with cancer in the last few 
months of their lives, a chemical that looks like it’s okay in mice that hasn’t been given to people 
before. It is actually fairly mind blowing when you stand back and think about it.”
“Pattern recognition is important, because the way we set up these studies, rather than everybody 
doing them, you have them concentrated in a small number of investigators and a small number of 
centres, so that they see the multiple patients getting treated with the same trial. So they have the 
opportunity of seeing that unusual, unexpected pattern recognition toxicity that would be diluted if 
a study of not very large patient sample size was diluted across too many centres.”
“If each centre only sees one or two patients, you lose the opportunity for pattern recognition.”
A centre is only as good as it’s last trial. Sponsors rely on the 
reputation of centres to form relationships and trust them with 
their trials.
“It’s a competitive business internationally to attract early phase 
trials to your centre, because we want opportunities for our 
patients (...) And there is a reputation that has to be acquired 
and maintained. And you know, they say football is only good as 
your last game, we’re only as good as our last trial. If we foul it 
up, that sponsor is unlikely to come and approach us anytime 
soon afterwards. So I think there is a reputation that comes from 
building up a critical mass of early phase trials in your centre, 
that you can convince people who have invested an awful lot 
of money to develop this novel compound to trust you with its 
development in the critical phase and early phase trials.”
“It’s about maintaining that relationship. And that comes down 
to whether you recruit the way (you said) you were going to do 
it, and whether you provided the data in a timely manner. Did 
you follow the protocol? Were there any concerns and serious 
protocol deviations?”
“(Something that is) emphasized in terms of building up a trials 
department and having commercial relationships with pharma is 
punctuality and robustness of communication. (...) And the more 
robustly you deliver their trial, with good assessments and good 
documentation, then the more likely they are to come to you with 
another trial.”
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Trials are not offering 
benefits to patients
Openness to patients
Need to explain 
correctly to gain 
informed consent
Very intensive and 
challenging for patients
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Get to know the 
patients better
Not necessarily 
right for every 
patient
Early phase trials 




lots of expertises 
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Good communication with 
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Spotting side effects and 
toxicity
Increasing patients’ 
awareness of their options
Right timing to talk to 
patients
Getting to know 
patients better
Long-term vision
The impact of COVID-19
on phase 1 trials
For this, participants were asked to share and 
reflect on their individual experiences during 
the COVID-19 crisis, as well as the long term 
impacts it would have on both the patient 
population and the people working in the 
field. 
They were then asked to identify the 
challenges and opportunities brought by the 
crisis and the adaptations that had to be 
made.
RESILIENCE
COVID-19 has highlighted the resilience and adaptability 
of cancer trialists and their network to continue patient 
support in the context of global disruption.
“There has been some positivity, I think I think it taught us 
all (...) how resilient we actually are.”
“If you look at the practice of oncology, it’s constantly 
changing, we’re always bringing in new therapies, new 
drugs, improvements in care. And one of things really 
impressed me about the pandemic is actually that progress 
has continued despite the pandemic. We’ve introduced new 
drugs, we’ve introduced new ways of treating people.”
There is a worry that the delayed diagnosis of patients, 
and the adaptations made during the pandemic will 
have serious long-term consequences that will be felt 
after COVID.
“So there will be patients that have had delayed 
diagnoses, and they will never get the treatments 
that they should have gotten. There will be delays, or 
there’ll be reduced numbers of trial options for a cohort 
of patients. They’ll be companies that don’t come to 
where they perceive high incidence of COVID to be, 
which obviously includes the UK, so they’ll be missing 
out on trial opportunities. I’m worried that some 
centres will lose most of their trial activity, because 
they weren’t able to get funding from things like the 
cancer charities. And I don’t think patients will want 
to travel in the same way that they used to. And, you 
know, then the patients may not want to be treated in 
the same way. So they might not want to have as many 
appointments and as many scans and maybe clinicians 
won’t want to do that either.”
Remote consultations have reduced travel time for patients 
seeking to take part in trials. Other measures, such as local 
blood tests and drug delivery, have been put in place for the 
benefit of patients.
Digital meetings have bridged silos by enabling people who 
would not usually be part of panels/meeting/talks, such 
as international collaborators or people from different 
disciplines, thus lowering the barrier of entry. Finally 
COVID-19 has highlighted the value of networks, as trialists 
leveraged international connections to get quick and 
accurate information about the virus and safety for patients.
“We’ve had, in an effort to kind of keep everyone updated 
and connected, a lot more meetings, and virtual meetings, 
not necessarily just within the group, but within the 
institute. And people can understand what other groups are 
doing. And so there has been a lot more kind of drive to kind 
of stay away from these silos, where you don’t know what’s 
going on within your own Institute.”
“And I think we really used our paediatric networks right 
at the beginning. So you know, we didn’t know whether 
children with cancer were going to be affected by COVID or 
not. So we literally just picked up the phone and emailed 
our colleagues in Italy, and in China, and just said, “Have 
you seen lots of cases?”. we didn’t have to wait for it to come 
out. And so actually, we had reassurance really quite early 
on in the pandemic, that there wasn’t going to be a major 
problem, because we literally had the paediatric oncologists 
from EU saying, “we haven’t seen a big problem”. So there’s, 
I think our paediatric networks really, really helped us at the 







COVID-19 has disrupted networking and communication, forcing rapid adaptation in switching to remote meetings and 
conferences. Whilst some opportunities have been missed, such as serendipitous chats in hallways and in conferences, trialists 
recognise the need to adapt to the circumstances and create new modalities of networking remotely.
“It’s all about collaboration. It’s all about talking to people, it’s all about networking. And, yes, there is a definite need and role 
for face to face meetings. But of course, you can never get everybody you want at a face to face meeting if they have to travel 
for days to get there. Now, there’s no excuse if you can get much better attendance when the whole meeting is on zoom. I think 
the really valuable lesson everybody has finally learned is that virtual meetings don’t work if half the people are real, and half 
the people are virtual, everybody has to be on an equal footing at the meeting. So I think we will have a clearer understanding 
of this meeting would be better run virtually, this is the meeting that needs to be face to face. And therefore will be able to be 
more inclusive, you be able to get the right people at the meeting. And it enabled us to have to and to interact differently, and 
hopefully to interact better. You know what the meeting behaviors interactions are different when you’re on a zoom call. We 
mustn’t assume that they’re all better.”
“One of the things that really worries me actually is virtual meetings, and working from home, are they fine as a sticking plaster? 
We thought this was done and dusted in three or four weeks, everybody went home with a laptop, sitting in their office at home, 
works fine for a few weeks. But if it’s permanent, then you do lose stuff. And these things will be permanent. And what really 
concerns me is, it works fine for me, because I’ve spent years building a network of people who do the work I do, I know who to 
talk to, I know how to how to deal with individuals. And then in 10 or 15 years time, they’ll be nobody who was here before. So 
how do we bring in new people, how do the new starters, the young, the new talent, build those networks? How do they know 
who to talk to? I’m not saying they have to do it the way I did it. But what we’ve put in place is sticking plasters. We’ve not put 
in place systems to build networks. And so we have to really think about that, and how we bring in new people. And it’s not just 
about training, it’s about it’s about those less tangible things around networking, and that’s really, really important in clinical 
trials research.”
“(Networking has suffered during COVID) because you’re not having those opportunistic meetings with people in the corridor of 
a conference, or we’re looking at the same post or whatever. But it hasn’t completely eliminated the opportunities to network, 
you still form them by knowing people through projects you’re working on, and being proactive in terms of engaging with sites 
where you already have involvement and getting to know the people who work there, but also they introduce you to other 
people. We’re going to go to fewer face to face conferences in the future. No matter what happens in the next six months or a 
year, people are going to go to more online conferences, because it’s cheaper, it’s more efficient with your time, it’s better for the 
environment, etc. We all have to think about our strategies for how we’re going to network in a new world where we’re leaving 
our house a bit less.”
The COVID-19 vaccine trials and the quick development of 
the vaccines has highlighted the value of trials in the public 
eye, and given a clear example of impact that trialists can 
refer to.
“I think if we can build on that, it will be great. Because we 
now have very concrete examples of how trials helped care 
in a very short time. I think it’s different, more difficult with 
cancer, where we found this target 20 years ago, and we 
found the drug 10 years ago, and then we did these trials, 
whereas it’s very condensed, the examples that you can give 
for COVID research.”
“I suppose the general public will better understand better 
what we do and then support their families to make those 
choices.”
“We’ve had examples of vaccine developed through clinical 
trial. If you want to think about trial impact, you’ve got 
basically an amazingly impactful number of trials, showing 






from families of 
patient’s choices
Challenges
“What changes or adaptation has been put in place as a result of COVID-19 that you 
are worried about/ are looking forward to get rid of”
Opportunities
“What changes or adaptation has been put in place as a result of COVID-19 that you 
hope will stay”
COVID-19 has 
put trials in the 
public eye
Very concrete 
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“ There’s something lost in the fact that you can’t have face to face conversations with 
people. Certainly with younger trainees, 
like myself, if you’re on an online meeting 
with 50 or 100 people, you’re not going to 
speak out and say something, whereas if 
you had the opportunity to really speak to 




























“ If you look at the practice of oncology, it’s constantly changing, we’re always bringing 
in new therapies, new drugs, improvements 
in care. And one of things really impressed 
me (...) is actually that progress has 
continued despite the pandemic. We’ve 
introduced new drugs, we’ve introduced 
new ways of treating people.



















Who makes a phase 1 trial 
happen?
A community of senior and early career 
oncologists were asked to pause and reflect 
on what experiences, values, behaviours, 
motivations, skills, mode and style of 
thinking, shape a successful cancer Phase 
1 trialist. Participants were asked about the 
skills and experience needed to be a trialist. 
The aim was to define the philosophy of 
people working in trials, their strengths and 
the value that they bring.
It’s my responsibility if things 
go wrong, and I would be very 
uncomfortable devolving that 














Keeping an open mind
“prepared for anything”
Dealing with the unexpected





























Due to the experimental nature of Phase 1 trials, 
trialists need to proactively look for signals in patients 
and have good pattern recognition to spot unexpected 
side effects. They also need the clinical and problem 
solving skills to then deal with these side effects 
appropriately.
Trialists keep an open mind and stay “prepared for 
anything”.
“I remember a little while ago, sitting with a patient, 
who had no toxicity from the previous cycle of 
treatment, but just was blinking and just looking 
slightly strange. And I’d asked her if her eyes were 
sore. And she said, No. So it’s just, it’s just these 
flashing lights that I’ve started seeing. And so picking 
up these side effects, we have an idea what the side 
effects may be, but we’re also more and more looking 
for unexpected side effects, and being open to those 
and having the clinical awareness to hopefully identify 
them, I think is important.”
“You need to have a pretty broad knowledge of 
medicine, to deal with unexpected side effects and good 
problem solving skills. There’s also telling apart toxicity 
from disease and from comorbidity as it’s important to 
understand what’s drug related, and what’s not.”
CURIOSITY
Cancer is a constantly evolving field, with new drugs, new 
treatments, new ways of working…
Trialists are curious people who keep up to date with 
changes and learn from others.
“We’re all going to need to have a lot more knowledge. As 
we go forward, you know, the science is becoming more and 
more specialized, and some of the side effects are really 
different for different types of drugs. So I think there’ll be 
a much bigger piece going forward about education, (...) 
People will need to be highly motivated and clever to be able 
to keep track of all of that.”
“I think it’s important to have the ability to first of all 
challenge the status quo. (...) It’s about being able to 
identify where the tangible unmet needs are.”
Communication is a key skill for working in early phase 
cancer trials, to collaborate with colleagues who have 
very diverse skills, coordinate with other centres, as well 
as talking closely with sponsors. Cancer trialists are also 
willing to have difficult discussions with patients.
“It’s in the nature of those trials, that you’re being very 
open with the patient about their their situation, the limited 
likelihood of benefits, the stage of their disease. It’s these 
conversations, which we welcome, which many colleagues 
may actually feel that they would prefer to avoid. (...) We 
tend to see the early phase trial patients more frequently. 
So we tend to be a smaller team looking after the early 
phase trial patients (...) I find myself getting to know these 
patients better.”
“One of the challenges I feel in the clinic is when patients 
come to see me as they will tomorrow morning. And they 
know they’ve got no treatment options left. They might 
agree with anything I suggest. However, unreasonable, 
uncertain, time consuming it is. The role of the research 
nurses in talking to patients and making sure they 
understand properly about the trials and aren’t just saying 
yes to anything”
“Clinical trials are probably the absolute epitome of 
teamwork and communication, because there’s so many 
different highly skilled individuals involved. And so to tie up 
the whole thing, everyone needs to talk to each other in a 
language that the other person understands. So I suppose 
this practice and awareness of what the colleagues’ scope of 
skills and language are to then tailor your (communication) 
accordingly. And you want to communicate effectively so 






Trialists are driven by wanting to improve care, and they see 
patients as partners. Openness and empathy are important skills 
to use at all times so that trials are designed and conducted in 
the most humane way possible, and their implications are made 
clear to patients. They take responsibility of their actions.
“It’s about a drive to want to make things better, and to 
understand what would make a patient want to participate in 
a trial. But it’s also about being able to give patients sufficient 
information that they can make an informed choice of what’s 
right for them. (...) You’ve got to want to seek to do better. You’ve 
also got to want to really understand what the patients want, 
which is often very different from what the investigator wants to 
do. And sometimes that can be really challenging bringing those 
things together.”
“(Amending) dosing protocols can really help (patients) with 
their treatment, and that brings satisfaction. You might be 
monitoring a patient who’s getting excessive toxicity, because 
they’re being dosed too high. Being able to (monitor drugs) is 
pretty great, because you’ve had some impact and can have 
impact for future patients as well, so that they don’t have to go 
through kind of excessive toxicity, or have the potential of being 
under-dosed.”
Because at the end of the day, if 
it’s not important to actual patients 
and the public, then it’s probably 
not something you should be 
focusing on. ”
“
The complexity and uncertain nature of Phase one trials requires 
trialists to be thorough throughout the research process and 
document with care and insight, ensuring evidence is recorded 
appropriately. Trialists bring their experience, insight and 
interpretation to complex data.
“Everything needs to be very well documented in everything 
that you’re doing, whether it’s taking samples, sending samples, 
noting adverse reactions or toxicity or response. If you want to 
make sense of what’s coming out at the end, it needs to all be 
well recorded. Sometimes just small things, like even the units of 
a dose might be wrong, that someone’s written down, and then 
kind of the interpretation of that later, can really impact your 
findings.”
“It’s about being very thorough, good documentation, following 
things through, but also being prepared to go into the unknown. 
With these new agents, I think you’ve got to know a bit about a 
lot of things. You need to know about if you’ve got a patient with 
a specific tumour type coming through, you need to quickly get 
your head around how their treatment pathway may have been, 
regardless of where they’ve come from. You need to be prepared 
to do a bit of background digging. You need to very much know 
the evidence that’s that’s coming through about different types 
of drugs and approaches, so that you’re not just thinking of your 







How are networks created and how do 
they evolve? Creating an optimal dynamic, 
leveraging skills and experiences by reaching 
across silos through curiosity and informal 
links.
Creating and maintaining networks requires making the effort to 
stay aware and curious of new things happening and reaching out 
to people. A large part of creating these networks is also the trust 
and reputation you have among peers.
“We often informally email people to say, you know, to ask advice 
or to ask, you know, have they got a trial for a patient?”
“In terms of establishing that network in the hospital, you are 
inheriting from those who were there before, but you won’t get 
any referrals from your colleagues unless you have credibility as 
a clinician and as a clinical researcher or somebody who’s going 
to take care of their patients.”
SMALL 
SCALE
The scale of Phase 1 trials makes networks especially important 
to share information and indentify patients.
“I think that’s also why we say we’ve got these wider link 
networks, whereas if you’re the huge juggernaut of a phase 
three, as a breast cancer doctor or a melanoma doctor, you don’t 
need a big network (...) to get, you know, the big trials come 
along, and they approach the centres. But we need the smaller 
interacting networks to identify the rare patients for precision 
medicine trials, the networks to attract trials in and the networks 
of people to work with. And then the complexity with some of the 
new treatments, we need networks within the hospital, to be able 
to give these cellular therapies and do it safely.”
Networks enable cancer professionals to exchange, integrate and 
share data, insights, knowledge and expertise in a collaborative 
manner contributing value and learning to all involved. 
Importantly they provide peer support. This dynamic stimulates 
network-wide effects, building, embedding and spreading 
excellence within a community of practice.
“I think (The ECMC network) has worked effectively to allow 
better referral of patients and better sharing of data. And I think 
that’s been taken up by the network as a whole. And we’ll be used 
as an example, going forward. And so we’ve all got different areas 
of expertise, we’ve got different patient populations. So it’s really 










Learning from others and sharing experiences and knowledge 
optimises time and is an accelerant for progress. It is 
important to keep a good awareness of the field, and a lack 
of understanding between stakeholders can be detrimental. 
Defragmentation and the breaking down of silos helps with 
organizational understanding and develops a respectful space for 
communication, learning and knowledge exchange.
“Because, you know, we all work in our little silos, but sometimes 
you don’t realize until you know, by chance here that someone 
half a mile down the road, does something exactly the same or 
has done before.”
“We’re all academics who work in universities. And it’s a mixed 
bag where they really understand what we do (...) I get frustrated 
sometimes being at senior management meetings when they 
say, well, clinical trials is just doing your day job (...) And it’s not 
that they don’t understand the reputational benefits and the 
infrastructure required, some do, not all people do. And I think 
(we need) continual education of ourselves and our colleagues.”
BRAIN 
DRAIN
Global partnerships are a critical to reducing the cancer burden. Whilst social inequalities in cancer 
are recognised in all countries, it is most apparent in low and/or middle-income (LMIC) countries 
such as Malawi, where it has major effects on the social fabric and the economy. This situation 
highlights an essential need to train and retain a range and depth of skilled and specialised 
individuals locally. The loss of local-based skilled individuals to opportunities in more affluent 
countries is an issue. However, through investment in human capacity and retention of skills and 
know-how, countries develop national ownership and an ability participate in global partnerships 
and networks.
‘(international) partnership works based on countries commitment to mutual respect to each other 
and importance of benefit to both countries’
‘(barriers can be resolved by) training and retaining enough personnel to work in various specialties 
of our healthcare system. Training is important but also creating an environment that will motivate 
and retain these trained personnel is crucial. There should be deliberated policies that do not only 
























































Need to train and retain a 
range and depth of skilled and 
specialised individuals locally
Critical to reduce the 
cancer burden
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Learning from treating 
childhood cancer
Improving outcomes for children and young 
adults with cancer requires a different model, 
ethos and approach to clinical trials and 
the patient. These experiences and ways of 
working in childhood cancer are of broader 
relevance to the cancer care community.
CHANGING 
POPULATION
Whilst emphasis is often placed on cancer in older age 
populations, it needs to be remembered that cancer affects 
all age groups including children. Therefore age may be 
important in determining care options and in post-cancer 
life.
“If you are dealing with the average cancer patient who is 
potentially quite elderly, and you are maybe not necessarily 
trying to just cure them, but extend their life a little bit, the 
things you measure are not necessarily the same as would 
be important to 30 year olds that you are hoping to cure, 
who then have another 40 years of life ahead of them.”
“We’re very interested in the side effects of treatment, 
because obviously, the peak age for childhood leukaemia 
is age two to five. And, you know, 90% of those children or 
nearly 93% now have been cured. And, you know, you hope 
when you cure them, they’re going to live to be like 80 or 90 
years old. And so, you’ve got to be very careful not only to 
cure the leukaemia, but that you haven’t done damage to 
their normal body cells that, okay, might be alright, for 10 
years or 20 years, but then might cause problems as they get 
older. So we have quite a different perspective in that way.”
QUALITY 
OF LIFE 
Cancer treatments are associated with side effects that can 
have both short term and long term impacts on a patients 
quality of life. Quality of life is highly personal and complex. 
With increased success in therapies, this aspect of cancer 
care is critical.
“It does need some innovative ideas about how to fund these 
things, and how to capture side effects and quality of life 
information in a rigorous way. These are really important to 
care for patients. And there’s a lot of problems around that. 
Because quality of life is very, very subjective. Whether life 
is good or bad is not really easily mapped on to anything 
objective. And so you can have someone you look at 
externally who can seem incredibly disabled and have very 
poor quality of life, who can say, “my life is great”, and vice 
versa, someone who seems to be functioning perfectly well, 
that says “my quality of life is awful”. So learning how to 
measure that is something we need to think about.”
SIDE
EFFECTS
Understanding and reducing side effects of treatments is 
an important yet often underrepresented aspect of cancer 
research. Side effects impact quality of life and bring a 
human-centred approach to clinical trial development.
“I think (side effects) are a really, really underappreciated 
thing by oncologists, and doctors in general. The side effects 
of treatment are really important to patients. It’s probably 
as important as curing their cancer, the things they have to 
live with, and I think it’s quite easy sometimes as a doctor to 
see something clinic and say, Alright, I’m going to prescribe 
you these medicines off, you go home and you don’t see 
what they’re having to deal with it at home. And, I think 
how cancer research is organized at the moment, we’re 
very bad at cataloguing and understanding side effects, 
that traditional clinical trials way of doing it of filling 
in these adverse event forms and things. We know from 
auditing trials, they’re incredibly inaccurate. So we both 
massively overreport, inaccurately report some types of side 
effects that are easy to measure, like, you know, blood test 
abnormalities or something and they massively under-report 
other other areas. And a lot of the time, they are just plain 
wrong, you know, once side effects are reported and actually 
we go back to patient notes, it was something different. So 






Patients are more willing to take an active role in looking for 
trials, and trialists understand the need to involve patients and 
patient representatives at all stages of a trial and its design to 
better understand their needs.
“So I think there is now that approach, and we get patients 
hunting for trials. There’s an informed patient population out 
there.”
“You’ll assume, as a clinician, that a patient wants to reduce 
number of visits or you know, wants to have tablets, instead of 
intravenous, or all of the ER make all these assumptions, and 
you won’t necessarily be right. They may find that coming to the 
hospital is actually very reassuring and they don’t want to reduce 
the frequency of visits. Or they may actually hate taking tablets 
and feel like they’re rattling all day, if they’re having to take 20 
tablets a day and prefer to come once every three weeks to have 
a drip. So, so we can’t assume that we know anything about the 
treatment pathway without checking the patients.”
“Patients aren’t as involved at the minute as they will be in the 
future. And I think public and patient involvement is becoming a 
much more important aspect of research. Having patient input to 
research decisions, even at an early stage is advantageous even 
from practical perspectives of the big additional commitment to 
going on to a phase one trial in terms of hospital visits and extra 
tests and extra blood tests and biopsies, etc. And, you know, 
patient representatives from an early stage can let you know 
what they think might be acceptable and what might not be 
acceptable, which can help in research and clinical trial planning 
from an early stage.”
CHANGING
POPULATION
The target population for First in Human Trials is changing, and 
including less terminal patients who haven’t exhausted their 
treatment options. This prompts a reconsideration of the side 
effects and long term effects of treatments.
“Increasingly, early phase trials are open patients who haven’t 
exhausted their standard treatment options. So then you’ve 
got a different dynamic, where you need to identify with the 
people looking after the patient, their primary team, a window 
of where it is reasonable to look at an experimental treatment, 
on the basis that they their condition won’t deteriorate, even if 
that treatment isn’t effective, and that you won’t have exhausted 
any of your your future treatments. So in breast cancer, we get 
patients who have reached the end of endocrine therapy, but 
who don’t have a pressing need to start chemotherapy. That’s an 
amazing opportunity, in that situation, to look at something that 
is more novel. So that there has been a move away from these 
patients being pre-terminal.”
These are themes we identified referring to 
changes, currently happening or predicted to 
happen, that would change the dynamic of 
trials and the way they are handled.
We mustn’t forget that this is still 





The growing size of Phase one trials disrupts their dynamic and 
brings a perceived dilution of the unique research opportunities 
afforded by their small scale.
“(there is a) changing nature of early phase trials. Because 
we are of a generation that remembers doing phase one trials 
where there was (...) 20 to 30 patients, but now you’ve got 
drugs been licensed on the basis of a phase one study where 
there’s 1000 patients (...) And with that has come perhaps the 
dilution of the balance between risk benefit and the anticipated 
benefit for patients as well, the perception has changed. And 
yeah, we mustn’t forget that this is still very much experimental 
medicine.”
“Pattern recognition is important, because the way we set up 
these studies, rather than everybody doing them, you have them 
concentrated in small number of investigators and small number 
of centres, so that they see the multiple patients getting treated 
with the same trial. So they have the opportunity of seeing that 
unusual, unexpected pattern recognition toxicity that would be 
diluted if a study of not very large patient sample size was diluted 
across too many centres.”
“Traditional phase one trialists would say that two or three 
centres is optimal. And if it’s a tumour specific or site specific 
trial, you’d say, not a huge number of centres, because it’s not 
(just) wanting ownership of the patients. If each centre only sees 
one or two patients, you lose the opportunity for that pattern 
recognition.”
“If you look at every possible combination of immunotherapy that 
could be done, there aren’t enough for patients and early phase 
trials in the world to do it. It is increasingly competitive. But it 




Digital Data collection tools offers new opportunities for 
monitoring patients and their quality of life more accurately.
Available and long-term access to Data streamlines the research 
process and allows comparison to similar datasets.
“We’ve been coming through patient reported outcome 
measures, where you capitalize on digital technology to get 
patients fill in apps and tell you how they’re feeling and, you 
know, day by day and collect more real time data.”
“Patients are going to want to do more remotely going forward, 
I think there will be much more electronic inputting. And I hope 
that we’ll move away completely from paper data entry. (We will) 
need to be much more aware of how to do electronic data entry. 
I’m hoping there’ll be a lot more access to source data so that we 
won’t have to start from scratch with everybody.”
“In our most recent trial, we’ve built in doing a test of brain 
function, a series of really short computer games, at the 
end of treatment, the basic tests kind of how well you can 
concentrate and memorize things and, and kind of plan your way 
through a maze and things like that. And on its own as a static 
measurement (...) it might answer a little bit of science, but not 
loads. But having got that we can then potentially go back and 
get people to repeat it in five years time. And we’ve got that 
baseline on all the children.”
“We have this huge potential to be much more efficient in the 
way we collect data, because the NHS collects a huge quantities 
of data routinely. And all that data is potentially linkable, 
collectible and analyzable. And you can use that to return 
information on trials and make progress. And that’s a massive 
potential to make things much more efficient.”
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Taking an active role 





We reflected on the future population that would take part in 
phase 1 trials, and the impact early detection and prevention 
strategies would have on the cancer population. How will the 
target population for First in Human Trials change in the Future 
(different tumour types / age groups / disease stage), and what 
impact will it have on trials? How will Trials have to adapt? For 
example, if a younger, less terminal population is taking part 
in Phase 1 trials, how will side effects and long term effects be 
considered? Will quality of life be measured differently?
COVID-19 has put clinical trials in the public eye and given a very 
concrete example to show the value of trials. In the future, how 
can the value of trials be more clearly communicated to promote 
public awareness?
Trialists will need an increasingly broad knowledge base. How 
can early career researchers get this experience, and gain more 
exposure to different types of cancer and treatments?
Phase One Trials currently benefit from the positive dynamics 
of working in a “niche” subject, with a small scale. What are 
the positives and what are ways to keep them in the future in a 
growing field?
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